Pharmaceuticals

Hepalink

Hepalink released FY2026 Q1 earnings on April 29 After-Market (BJT), actual revenue CNY 1.331 B, actual EPS CNY 0.1278

Hepalink FY2026 Q1 Earnings Release Scheduled for April 29 After-Market BJT

Hepalink released FY2025 annual earnings on March 30 After-Market (BJT), actual revenue CNY 5.479 B (forecast CNY 5.315 B), actual EPS CNY 0.2382 (forecast CNY 0.57)

Hepalink released FY2025 Q4 earnings on March 30 After-Market (BJT), actual revenue CNY 1.285 B (forecast CNY 1.153 B), actual EPS CNY -0.1391

Hepalink to Release FY2025 Earnings on March 30 After-Market (BJT), Forecast Revenue CNY 5.315 B, EPS CNY 0.57

Hepalink released FY2025 Q3 earnings on October 30 After-Market (BJT), actual revenue CNY 1.377 B (forecast CNY 1.409 B), actual EPS CNY 0.0897

Hepalink released FY2025 9 Months Earnings on October 30 After-Market (BJT), actual revenue CNY 4.194 B, actual EPS CNY 0.3773

Hepalink to Release FY2025 Q3 Earnings on October 30 After-Market (BJT), Forecast Revenue CNY 1.409 B

Hepalink released FY2025 Q2 earnings on August 29 After-Market (BJT), actual revenue CNY 1.423 B (forecast CNY 1.279 B), actual EPS CNY 0.1808

Hepalink released FY2025 Semi-Annual earnings on August 29 After-Market (BJT), actual revenue CNY 2.817 B, actual EPS CNY 0.2875

Hepalink to Release FY2025 Semi-Annual Earnings on August 29, 2025 (BJT)

H1710 Enters Clinical Assessment Stage

H1710, a New Drug Developed by Hepalink, Completes First Patient Dosing in Phase I Clinical Trial

Hybrivia Pharmaceuticals Submits New Trademark Applications

Huapu's Enoxaparin Sodium Injection Receives EMA Approval for New Manufacturer

Hepalink Announces Final Dividend for 2024

Hepalink Receives EMA Approval for New Production of Enoxaparin Sodium Injection

Hepalink Announces Final Dividend Distribution for July 22, 2025

Huipu Releases 2025 Q1 Financial Report

Hyphary's TDMed Receives Approval for Enoxaparin Sodium Injection in South Africa

002399

Resverlogix Corp. has announced a one-year extension of its US$6.0 million secured debenture with Shenzhen Hepalink Pharmaceutical Group, moving the maturity date to May 13, 2027. The interest rate will increase from 18% to 20% per annum starting May 14, 2026. CEO Donald McCaffrey expressed appreciation for Hepalink's support. Resverlogix focuses on developing epigenetic therapies for chronic diseases, particularly cardiovascular conditions.

StockTitan

HEPALINK

Resverlogix Announces One-Year Extension of Debenture | RVXCF Stock News

09989

HEPALINK announced its full-year results for the year ended December last year, with a revenue of RMB 5.438 billion, an increase of 3.4% year-on-year. The net profit was RMB 349 million, a decrease of 46% year-on-year; earnings per share were RMB 0.24. A final dividend of 14.5 cents was declared, compared to 25 cents in the same period last year

AASTOCKS

"Performance" Hepalink's annual net profit of RMB 349 million fell by 46%, with a final dividend of 14.5 cents per share

STECH

09698

36Kr learned that the Hang Seng Index opened up 0.06%, while the Hang Seng TECH Index fell 0.11%; the software services, automotive, and pharmaceutical sectors led the gains, with GDS rising over 4%, and Nio, XPeng, and Hepalink rising over 1%; the semiconductor, non-ferrous metals, and media sectors weakened, with SMIC, Northern Mining, and Kuaishou falling over 1%

36Kr

Hang Seng TECH Index

GDS-SW

The Hang Seng Index opened up 0.06%, while the Hang Seng TECH Index fell 0.11%

Shenzhen Hepalink Pharmaceutical Group Co., Ltd. has released its unaudited Q3 financial report for 2025, covering the nine months ending September 30. The report, approved by the board, emphasizes transparency and regulatory compliance, which may enhance investor confidence. The latest analyst rating for its stock (HK:9989) is a Sell, with a price target of HK$4.31. The company operates in the pharmaceutical sector and is listed on the Hong Kong Stock Exchange, with a current market cap of HK$17.59B.

Tip Ranks

Shenzhen Hepalink Releases 2025 Q3 Financial Report

Hepalink(002399.SZ)

Resverlogix Announces One-Year Extension of Debenture | RVXCF Stock News

"Performance" Hepalink's annual net profit of RMB 349 million fell by 46%, with a final dividend of 14.5 cents per share

The Hang Seng Index opened up 0.06%, while the Hang Seng TECH Index fell 0.11%

Shenzhen Hepalink Releases 2025 Q3 Financial Report